Trial Profile

Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Dec 2022 Results(4-year results) assessing Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies through January 2019 published in the Epilepsia
22 Apr 2021 Results Evaluating the effect of CBD on convulsive (clonic, tonic, tonic-clonic, atonic, focal to bilateral tonic-clonic) and nonconvulsive (focal, absence, myoclonic, myoclonic-absence, spasms) seizures and safety in patients with TREs in the EAP presented at the 73rd Annual Meeting of the American Academy of Neurology
13 Apr 2021 According to a GW Pharmaceuticals media release, results of this trial will be presented at the 2021 American Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com